News

2 Women on Mission to Raise Awareness in Latino Community

When Enma Espinosa worked during the day and her husband, Francisco Espinosa, worked the night shift, they barely saw each other. So it took longer for her to realize the small changes in his cognition were not just a normal part of aging. It wasn’t until her husband’s barber called…

UK Groups Want Rights for Care-home Visitors During COVID-19 Pandemic

A coalition of dementia organizations is calling on the U.K. government to help care-home residents maintain physical contact with loved ones during the COVID-19 pandemic. Called One Dementia Voice, the coalition acknowledges the difficulties of balancing the risk of COVID-19 against the potential harm done by isolation. However, it…

EMA Committee Votes Against Approving Aduhelm in Europe

A European Medicines Agency (EMA) committee has voted against approving Biogen’s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. The EMA’s Committee for Medicinal Products for Human Use, known as CHMP, is expected to issue a formal ruling based on this so-called negative trend vote after its meeting in…

Lower Levels of Tau Marker Seen With Aduhelm in Phase 3 Trials

Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive and functional decline in Alzheimer’s patients, according to a recent data analysis of two Phase 3 clinical trials. The data, analyzed from around 7,000 blood samples collected from more than…

AC Immune Extends Work Into TDP-43 Protein’s Role in Alzheimer’s

AC Immune has announced it will extend its partnership with researchers at the University of Pennsylvania to further study the mechanisms underlying disease-causing changes in  the transactive response DNA binding protein 43 kDa (TDP-43). Specifically, company researchers and those with the university’s Center for Neurodegenerative Disease Research at the Perelman School of Medicine…